Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: new IRA concerns and legal action in the US; Biogen brings in another ex-Sanofi exec; Novartis buys into kidney disease; and China appears to be raising the regulatory bar in the immune-oncology space.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 16 June 2023, including: new IRA concerns and legal action in the US; Biogen, Inc. brings in another ex-Sanofi exec; Novartis AG buys into kidney disease; and China appears to be raising the regulatory bar in the immune-oncology space.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly Sidelined Three Drugs Due To IRA, CEO Ricks Says" - Scrip, 14 Jun, 2023.)
(Also see "What To Expect As IRA Legal Challenges Mount" - Scrip, 12 Jun, 2023.)
(Also see "Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over" - Scrip, 13 Jun, 2023.)
(Also see "Novartis Aims To Fly High In Kidney Disease With Chinook Buy" - Scrip, 12 Jun, 2023.)
(Also see "Chinese Regulator Rejects Domestic PD-1/L1 Contender In Latest Tightening Signal" - Scrip, 14 Jun, 2023.)